

Anti-DKK1 Reference Antibody (Sirexatamab)

Catalog # APR11203

Product Information

Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	O94907
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG4SP-FALA-noK
Calculated MW	28672

Additional Information



Target/Specificity	DKK1
Expression system	CHO

Protein Information


Name	DKK1
Function	Antagonizes canonical Wnt signaling by inhibiting LRP5/6 interaction with Wnt and by forming a ternary complex with the transmembrane protein KREMEN that promotes internalization of LRP5/6 (PubMed: 22000856). DKKs play an important role in vertebrate development, where they locally inhibit Wnt regulated processes such as antero-posterior axial patterning, limb development, somitogenesis and eye formation. In the adult, Dkks are implicated in bone formation and bone disease, cancer and Alzheimer disease (PubMed: 17143291). Inhibits the pro-apoptotic function of KREMEN1 in a Wnt-independent manner, and has anti-apoptotic activity (By similarity).
Cellular Location	Secreted.
Tissue Location	Placenta.

Images

Anti-DKK1 Reference Antibody (Sirexatamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.



The purity of Anti-DKK1 Reference Antibody (Sirexatamab) is 98%, determined by SEC-HPLC.



Immobilized Human DKK1-TEV-6His at 2 µg/mL can bind Sirexatamab, EC50= 0.009958 µg/mL.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.